

Transcutaneous supraorbital nerve stimulation enhances somatosensory thalamic activity in migraine between attacks: a central mechanism of clinical efficacy?



Davide Di Lenola¹, Gianluca Coppola², Mariano Serrao¹, Cherubino Di Lorenzo³, Francesco Pierelli¹

"Sapienza" University of Rome Polo Pontino, Department of medico-surgical sciences and biotechnologies, Latina, Italy
G.B. Bietti Foundation IRCCS, Department of Neurophysiology of Vision and Neurophthalmology, Rome, Italy
Don Carlo Gnocchi Onlus Foundation, Milan, Italy

BACKGROUND

■ In a recent randomized double-blind sham-controlled study the Cefaly®, a novel transcutaneous supraorbital electrostimulation device, has been successfully used as a prophylactic treatment for episodic migraine (Schoenen et al., 2013).

• The possible mechanisms of action through which the device is able to induce clinical improvement in migraine are not known.

In the present study, we investigated whether Cefaly® may act centrally at the thalamocortical/cortical level.

DESIGN & METHODS

• To explore the central mechanisms of action of Cefaly®, we have recorded the somatosensory evoked potentials (SSEPs) before, and twice (intersession interval of 5 minutes) after one session of supraorbital stimulation lasting 20min in 10 migraine without aura patients between attacks.

• We measured the N20-P25 amplitudes on the low-frequency-SSEP, and, after applying a band-pass filter (450-750 Hz), maximal peak-to-peak amplitudes of the <u>pre-synaptic</u>, reflecting thalamocortical activity, and <u>post-synaptic</u>, reflecting primary cortical activation, high-frequency oscillations (HFOs) (Coppola et al., 2005).

RESULTS

Pre-synaptic HFO amplitudes, reflecting somatosensory thalamocortical activity, significantly increased immediately after the end of the supraorbital stimulation with Cefaly® (from 0.035 μ V to 0.058 μ V, p<0.01), but recovered to the pre-stimulation values as early as 5 minutes later. Both the low-frequency N20-P25 SSEP component and post-synaptic HFOs were unaffected by Cefaly ®.

DISCUSSION

Present data might support the hypothesis that Cefaly® acts centrally through increased thalamocortical activity induced by the neurostimulation.

• It is of obvious interest to verify whether these device-induced changes might persist at long-term after 3-month daily preventive stimulation, and if they follow clinical improvement.





Pre-synaptic HFO amplitudes, reflecting somatosensory *thalamocortical activity*, significantly increased after the supraorbital stimulation with Cefaly®.



Post-synaptic HFOs, reflecting *primary cortical activation*, were unaffected by 20 min supraorbital stimulation with Cefaly®.



Low-frequency N20-P25 SSEP amplitude were unaffected by 20 min supraorbital stimulation with Cefaly®.

REFERENCES

Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gérard P, Magis D. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013 Feb 19;80(8):697-704.

Coppola G, Vandenheede M, Di Clemente L, Ambrosini A, Fumal A, De Pasqua V, Schoenen J. Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks. Brain. 2005 Jan;128(Pt 1):98-103.